Phase 1b Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatmentof Advanced Solid Tumors (MINOTAUR Study)
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans. Cancers include esophageal cancer and colon and rectal cancer.
Ryan Moy, MD
|Are you at least 18 years old?
|Have you been diagnosed with colon, esophageal, or GI cancer?